Product Name: EPAC2 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: EPAC2 antibody can be used for detection of EPAC1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: EPAC2 antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of human EPAC2.The immunogen is located within the first 50 amino acids of EPAC2.
Host Species: Rabbit
Purification: EPAC2 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 1056634-68-4
Product: CYT387
Buffer: EPAC2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: EPAC2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: EPAC2 Antibody: 2, EPAC, CGEF2, EPAC2, EPAC 2, Nbla00496, CAMP-GEFII, Rap guanine nucleotide exchange factor 4, Exchange factor directly activated by cAMP 2
Accession NO.: NP_008954
Protein Ino: 155030204
Official Symbol: RAPGEF4
Geneid: 11069
Background: EPAC2 Antibody: EPAC2, also known as Rap guanine nuclear exchange factor 4 and cAMPGEF-II, is belongs to a family of cyclic adenosine monophosphate (cAMP) binding proteins with guanine nucleotide exchange factor. Like the related protein EPAC1, EPAC2 signaling plays a role in numerous cellular processes such as integrin-mediated cell adhesion, muscle contraction, learning and memory, cell proliferation, and inflammation. Recent evidence suggests that EPAC2 induces synapse remodeling and depression, with mutations in its gene being found in patients with autism.
PubMed ID:http://aac.asm.org/content/39/11/2583.abstract
